 |
42 Diseases |  |
114 Trials |
|
114 Trials |  |
1654 News |  |
| «12...19202122232425262728293031» |
- Enrollment open, Enrollment change, Trial initiation date, Metastases: A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer (clinicaltrials.gov) - Sep 12, 2014
P1, N=24, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting | N=42 --> 24 | Initiation date: Apr 2014 --> Aug 2014
- |||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Enrollment open, Trial primary completion date: INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer (clinicaltrials.gov) - Sep 11, 2014
P3, N=588, Recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Not yet recruiting --> Recruiting | N=42 --> 24 | Initiation date: Apr 2014 --> Aug 2014 Suspended --> Recruiting | Trial primary completion date: Dec 2016 --> Dec 2019
- |||| Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: MDA-CCOP-2004-0305: Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Sep 11, 2014
P2, N=80, Completed, Sponsor: M.D. Anderson Cancer Center
Suspended --> Recruiting | Trial primary completion date: Dec 2016 --> Dec 2019 Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Sep 2014
- Trial primary completion date, Combination therapy: Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Sep 10, 2014
P1/2, N=74, Active, not recruiting, Sponsor: Moshe Talpaz, M.D.
Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Sep 2014 Trial primary completion date: Jan 2017 --> Apr 2009
- sirolimus / Generic mfg.
Trial primary completion date, Immune cell: Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers (clinicaltrials.gov) - Sep 10, 2014
P2, N=510, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2017 --> Apr 2009 Trial primary completion date: Jun 2015 --> Dec 2021
- Rituxan (rituximab) / Roche
Trial primary completion date: Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma (clinicaltrials.gov) - Aug 25, 2014
P2, N=25, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Jun 2015 --> Dec 2021 Trial primary completion date: Oct 2014 --> Oct 2015
- || guadecitabine (SGI-110) / Otsuka
Trial primary completion date, Combination therapy: SGI-110 in Combination With Carboplatin in Ovarian Cancer (clinicaltrials.gov) - Aug 21, 2014
P1/2, N=116, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Trial primary completion date: Oct 2014 --> Oct 2015 Trial primary completion date: Jul 2014 --> Jan 2015
- pegylated liposomal doxorubicin / Generic mfg., nintedanib / Generic mfg.
Enrollment change, Trial termination, Combination therapy: Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer (clinicaltrials.gov) - Aug 21, 2014
P1/2, N=11, Terminated, Sponsor: Hoosier Cancer Research Network
Trial primary completion date: Jul 2014 --> Jan 2015 N=41 --> 11 | Suspended --> Terminated; Funding withdrawn due to drug unavailability
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma
Trial primary completion date, Combination therapy: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 15, 2014
P1, N=18, Recruiting, Sponsor: Gynecologic Oncology Group
N=41 --> 11 | Suspended --> Terminated; Funding withdrawn due to drug unavailability Trial primary completion date: Jul 2014 --> Oct 2014
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, veliparib (ABT-888) / AbbVie
Trial primary completion date, PARP Biomarker, Metastases: Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (clinicaltrials.gov) - Aug 12, 2014
P1, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2014 --> Oct 2014 Trial primary completion date: Mar 2014 --> Dec 2014
- pegylated liposomal doxorubicin / Generic mfg., carfilzomib / Generic mfg.
Clinical: Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 8, 2014
P1/2, N=53, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Mar 2014 --> Dec 2014 Trial primary completion date: Jul 2014 --> Jul 2015
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (clinicaltrials.gov) - Aug 8, 2014
P1, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2014 --> Jul 2015 Not yet recruiting --> Recruiting
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Metastases: Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer (clinicaltrials.gov) - Aug 5, 2014
P1/2, N=46, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (clinicaltrials.gov) - Aug 4, 2014
P1, N=40, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jun 2022 --> Jun 2023
- Trial primary completion date, Metastases: A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer (clinicaltrials.gov) - Aug 1, 2014
P1, N=42, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Jun 2022 --> Jun 2023 Trial primary completion date: Feb 2016 --> Mar 2015
- ||||| Ninlaro (ixazomib) / Takeda
Clinical: Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients (clinicaltrials.gov) - Aug 1, 2014
P1/2, N=60, Not yet recruiting, Sponsor: Oncotherapeutics
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (clinicaltrials.gov) - Jul 30, 2014
P1, N=40, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- pegylated liposomal doxorubicin / Generic mfg., nintedanib / Generic mfg.
Trial primary completion date, Combination therapy: Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer (clinicaltrials.gov) - Jul 18, 2014
P1/2, N=41, Suspended, Sponsor: Hoosier Cancer Research Network
Trial primary completion date: Feb 2016 --> Mar 2015 Trial primary completion date: Jun 2014 --> Jun 2015
- Enrollment change, PARP Biomarker: Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (clinicaltrials.gov) - Jul 17, 2014
P1, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Jun 2015 N=66 --> 48
- | Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
New P1/2 trial: Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 12, 2014
P1/2, N=47, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- |||| Trial primary completion date, Monotherapy: Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma (clinicaltrials.gov) - Jul 8, 2014
P3, N=646, Completed, Sponsor: Janssen Research & Development, LLC
N=66 --> 48 Trial primary completion date: Dec 2014 --> May 2014
- ||||||| Trial completion, Trial primary completion date, Monotherapy: Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma (clinicaltrials.gov) - Jul 8, 2014
P3, N=646, Completed, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Dec 2014 --> May 2014 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2014
- Istodax (romidepsin) / Astellas, BMS
Trial initiation date, Combination therapy, Epigenetic controller: Phase I Dose-finding and Preliminary Efficacy Study of the Istodax (clinicaltrials.gov) - Jul 4, 2014
P1, N=24, Recruiting, Sponsor: Weiyun Ai
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2014 Initiation date: Sep 2013 --> Apr 2014
- Istodax (romidepsin) / Astellas, BMS
Enrollment open, Trial initiation date, Combination therapy, Epigenetic controller: Phase I Dose-finding and Preliminary Efficacy Study of the Istodax (clinicaltrials.gov) - Jul 4, 2014
P1, N=24, Recruiting, Sponsor: Weiyun Ai
Initiation date: Sep 2013 --> Apr 2014 Not yet recruiting --> Recruiting | Initiation date: Sep 2013 --> Apr 2014
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma (clinicaltrials.gov) - Jul 2, 2014
P1/2, N=19, Completed, Sponsor: SCRI Development Innovations, LLC
Not yet recruiting --> Recruiting | Initiation date: Sep 2013 --> Apr 2014 Trial primary completion date: Jun 2013 --> Jun 2012
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin (clinicaltrials.gov) - Jul 2, 2014
P2, N=32, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Jun 2013 --> Jun 2012 Trial primary completion date: Aug 2016 --> Jun 2018
- | Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Trial primary completion date, Metastases: Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma (clinicaltrials.gov) - Jul 2, 2014
P1/2, N=19, Completed, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Aug 2016 --> Jun 2018 Active, not recruiting --> Completed | Trial primary completion date: Jun 2013 --> Jun 2012
- || volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial primary completion date, Monotherapy: BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer (clinicaltrials.gov) - Jun 27, 2014
P2, N=110, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | Trial primary completion date: Jun 2013 --> Jun 2012 Trial primary completion date: Oct 2011 --> Jun 2014
- |||| volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial completion, Trial primary completion date, Monotherapy: BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer (clinicaltrials.gov) - Jun 27, 2014
P2, N=110, Completed, Sponsor: Boehringer Ingelheim
Trial primary completion date: Oct 2011 --> Jun 2014 Active, not recruiting --> Completed | Trial primary completion date: Oct 2011 --> Jun 2014
- Avastin (bevacizumab) / Roche
Trial primary completion date, Monotherapy, IO biomarker, Metastases: Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma (clinicaltrials.gov) - Jun 26, 2014
P2, N=26, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Oct 2011 --> Jun 2014 Trial primary completion date: Mar 2015 --> May 2016
- || trebananib (AMG 386) / Amgen
Trial primary completion date, Combination therapy, Metastases: AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR (clinicaltrials.gov) - Jun 19, 2014
P1, N=103, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Mar 2015 --> May 2016 Trial primary completion date: Jun 2014 --> Sep 2014
- ||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Clinical: Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON) (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: ARCAGY/ GINECO GROUP
- Trial primary completion date, Combination therapy: Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2014
P1/2, N=78, Active, not recruiting, Sponsor: Moshe Talpaz, M.D.
Trial primary completion date: Jun 2014 --> Sep 2014 Trial primary completion date: Oct 2013 --> Jan 2017
- Enrollment change, Combination therapy, Metastases: BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (clinicaltrials.gov) - May 27, 2014
P1, N=19, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Oct 2013 --> Jan 2017 N=24 --> 19
- Enrollment closed, PARP Biomarker: Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (clinicaltrials.gov) - May 26, 2014
P1, N=66, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=24 --> 19 Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche
Trial completion, Metastases: Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer (clinicaltrials.gov) - May 25, 2014
P2, N=84, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
Enrollment open, Surgery: Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (clinicaltrials.gov) - May 20, 2014
P=N/A, N=50, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
Trial initiation date, Surgery: Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (clinicaltrials.gov) - May 20, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Initiation date: Dec 2013 --> Dec 2014
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date, Combination therapy: Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas (clinicaltrials.gov) - May 19, 2014
P2, N=68, Active, not recruiting, Sponsor: University of Southern California
Initiation date: Dec 2013 --> Dec 2014 Trial primary completion date: Jun 2014 --> Jun 2014
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion date, Combination therapy: Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas (clinicaltrials.gov) - May 19, 2014
P2, N=68, Active, not recruiting, Sponsor: University of Southern California
Trial primary completion date: Jun 2014 --> Jun 2014 Trial completion date: Jun 2015 --> Jun 2015
- || volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial completion date, Monotherapy: BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer (clinicaltrials.gov) - May 18, 2014
P2, N=110, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Jun 2015 --> Jun 2015 Trial completion date: Jun 2014 --> Oct 2014
- || Vynfinit (vintafolide) / Novartis
Trial suspension, Combination therapy: Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (clinicaltrials.gov) - May 18, 2014
P3, N=640, Suspended, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jun 2014 --> Oct 2014 Recruiting --> Suspended
- || guadecitabine (SGI-110) / Otsuka
Trial primary completion date, Combination therapy: SGI-110 in Combination With Carboplatin in Ovarian Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=116, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Recruiting --> Suspended Trial primary completion date: Jul 2013 --> Jul 2014
- || guadecitabine (SGI-110) / Otsuka
Trial completion date, Combination therapy: SGI-110 in Combination With Carboplatin in Ovarian Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=116, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Trial primary completion date: Jul 2013 --> Jul 2014 Trial completion date: Jul 2014 --> Jul 2015
- ||| guadecitabine (SGI-110) / Otsuka
Enrollment closed, Combination therapy: SGI-110 in Combination With Carboplatin in Ovarian Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=116, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Trial completion date: Jul 2014 --> Jul 2015 Recruiting --> Active, not recruiting
- Herceptin (trastuzumab) / Roche
Trial initiation date, Metastases: Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer (clinicaltrials.gov) - May 6, 2014
P2, N=84, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Initiation date: Oct 2000 --> Jan 2001
- pegylated liposomal doxorubicin / Generic mfg., lapatinib / Generic mfg.
New P1 trial, Combination therapy, Metastases: A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer (clinicaltrials.gov) - May 4, 2014
P1, N=12, Recruiting, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
- ||||||| Trial completion, Monotherapy, Metastases: A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer (clinicaltrials.gov) - Apr 20, 2014
P3, N=751, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Initiation date: Oct 2000 --> Jan 2001 Active, not recruiting --> Completed
- ||| motolimod (VTX 2337) / BMS
Enrollment closed, Combination therapy: VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Apr 13, 2014
P2, N=290, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| pegylated liposomal doxorubicin / Generic mfg., pomalidomide / Generic mfg.
Clinical: Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 6, 2014
P1/2, N=68, Recruiting, Sponsor: Oncotherapeutics
Recruiting --> Active, not recruiting N=40 --> 68